ClinicalTrials.gg
RecruitingNCT07400991RELIEF-AHFUpdated May 7, 2026

Restrictive Versus Liberal Fluid Intake in Acute Decompensated Heart Failure

An interventional study of Fluid restriction strategy and Thirst-driven, liberal fluid intake in Acute Heart Failure (AHF), sponsored by Gødstrup Hospital. Recruiting at 1 site in Denmark. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-05-07.

Sponsored by Gødstrup Hospital · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Started May 2026; still recruiting 6 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
420
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 242 studies in Heart Failure with a site in Denmark — 52 open to participants now, 60 under way, 9 of them phase 3. Heart Failure · Denmark.

Planned enrollment
78th of 187
420 · median 197
Started
2026
with 11 others
No phase
89 of 242
20 open now
Primary completion
2029-05
later than 42 of 59 live
Registered
232nd of 242
by date

Among the 242 studies in Heart Failure with a site in Denmark, this one is the 78th largest by planned enrollment of the 187 interventional ones that give a count, is one of 12 that started in 2026, is one of 89 with no phase, reaches primary completion later than 42 of the 59 other live ones, and was the 232nd registered.

Heart Failure

6,340 studies on the registry are indexed under Heart Failure; 1,397 are open to participants now.

Browse Heart Failure studies →

Open to participants now

52 of the 242 studies in Heart Failure with a site in Denmark are open now. Recruiting first, the newest first:

46 more — sign in →

All 52 open studies →

A study can be open while its sites in Denmark have not opened yet or have stopped. Only those recruiting at a site in Denmark →

Who these studies take

Of the 968 Heart Failure studies recruiting now, 691 (71%) set no upper age limit and 90 (9%) stop at 75 or younger; 64 take children under 18; 97 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 242 studies in Heart Failure with a site in Denmark, or all of them as a file.
02

Study summary

The aim of this clinical trial is to learn whether a thirst-driven, liberal fluid-intake strategy is comparable to a fluid-restriction strategy in patients hospitalized for acute decompensated heart failure (ADHF). The study will also assess the safety of the intervention and its effects on thirst and quality of life.

Patients hospitalized with ADHF will be asked to follow either a thirst-driven fluid-intake strategy or a fluid-restriction strategy during their hospital stay and for one month after discharge.

03

Conditions studied

  • Acute Heart Failure (AHF)

Browse trials for

Keywords

  • Fluid Restriction
  • Thirst-driven fluid intake
  • Liberal fluid intake
  • Acute heart failure
  • Time to clinical stability
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Age >18 years
  2. Hospitalized for ADHF as the primary diagnosis, meeting both of the following:

    1. ≥1 documented symptom of new or worsening heart failure (dyspnea, fatigue, decreased exercise tolerance, or symptom of end-organ hypoperfusion).
    2. Objective evidence of ADHF, defined as either:

    i. ≥2 physical signs (edema, ascites, pulmonary rales/crackles, increased JVP, S3 gallop, rapid weight gain due to fluid retention), OR ii. ≥1 physical sign AND ≥1 laboratory finding indicative of ADHF (BNP >500 ng/L or NT-proBNP >2000 ng/L if sinus rhythm, or BNP >750 ng/L or NT-proBNP >3000 ng/L if atrial fibrillation, radiological/ultrasound evidence of pulmonary congestion, echocardiographic sign [VCI >2.1 cm, LVOT VTI \<15 cm, E/e' >14, D-dominant pulmonary venous inflow pattern], or invasive evidence [CVP >12 mmHg, PCWP >18 mmHg, CI \<2.2 L/min/m2]).

  3. Treatment with ≥40 mg IV furosemide (or equivalent)
  4. Enrolment within 24 hours of admission
  5. Ability to provide

Exclusion criteria

Exclusion Criteria:

  1. Requirement at admission for ICU-level care, or IV inotropic/vasopressor therapy for ADHF.
  2. Na+ \<125 mmol/L or Na+ >145 mmol/L.
  3. End-stage chronic kidney disease on chronic dialysis or \<15 mL/min/1.73 m2
  4. Any condition which would make participation unsafe or substantially affect protocol adherence, as judged by investigator.
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Outcomes assessor)
Enrollment
420 participants (estimated)

Study arms

  • Experimental
    Thirst-driven, liberal fluid intake

    Behavioral: Thirst-driven, liberal fluid intake

  • Active comparator
    Fluid restriction

    Behavioral: Fluid restriction strategy

Interventions

  • BehavioralFluid restriction strategy

    Fluid restriction of 1.5 L/day

  • BehavioralThirst-driven, liberal fluid intake

    Liberal fluid intake driven by thirst without restrictions

06

What researchers measure

Primary outcomes

  1. Time to clinical stability

    Time from randomization to clinical stability. Clinical stability is defined as: 1. Off IV loop diuretics for ≥ 24 hours without need for reinitiation of IV diuretics. 2. No evidence of pulmonary congestion, defined as both: i) No new or worsening dyspnea at rest compared with status at admission ii) Clear lung auscultation or clinically improved, or normal lung and/or vena cava ultrasound without evidence of congestion. 3. No new or worsening peripheral edema compared with status at admission.

    Time frame: From enrollment to 1 month follow-up

Secondary outcomes

  1. Thirst Distress

    Thirst Distress Scale for patients with Heart Failure (TDS-HF). Scores range from 8 to 40. Higher scores indicate greater thirst-related distress

    Time frame: From enrollment to 1 month follow up

  2. Patient-perceived Quality of Life

    Kansas City Cardiomyopathy Questionnaire (KCCQ). Scores range from 0 to 100, with higher scores indicating better health status.

    Time frame: From enrollment to 1 month follow up

  3. Incidence of Treatment-Emergent Adverse Events (Safety and Tolerability)

    Number of occurrences during hospitalization of clinical worsening (escalation of HF therapy, such as vasopressor/inotrope initiation, ICU transfer, dialysis, reinitiation of IV diuretics), electrolyte disturbances, worsening renal function, or in-hospital death, and similarly after one month including HF hospitalization

    Time frame: From enrollment to 1 month follow up

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: Undecided — Due to regulations by Region Committees on Health Research Ethics

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started May 2026 (actual). Primary completion is estimated for May 2029, 36 months after the start.

Of 1,119 non-industry interventional studies with no phase under Heart Failure, half reached primary completion within 29 months of starting (the median), counting those still running; a quarter within 16 and three quarters within 50. This study's planned 36 months is above that.

Counting every sponsor, half of 1,355 studies reached it within 31 months; a quarter within 16 and three quarters within 52.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 3, 2026
First posted
Feb 10, 2026
StartActual
May 1, 2026
Primary completionEst.
May 1, 2029
CompletionEst.
Aug 2029
Last update
May 7, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 7, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07400991
Lead sponsor
Gødstrup Hospital
Responsible party
Sponsor
First posted
Feb 10, 2026
Start date
May 1, 2026
Primary completion
May 1, 2029 (estimated)
Completion
Aug 2029 (estimated)
Last update
May 7, 2026

Study contacts

Anders Hostrup Larsen, MD, PhD
Contact
anders.hostrup@rm.dk
0045

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion